

Johnson & Johnson Innovative Medicine	Data Sharing Request Due Diligence Assessment
---	--

General Information	
YODA Project (Protocol) ID:	2026-0576
Date Proposal Received by YODA Project:	24-Jul-2026
Product Name(s):	Erdafitinib (BALVERSA®)
Condition(s) Studied:	Urothelial Cancer
NCT Number(s), Protocol Number(s) and Title(s):	NCT03390504 - 42756493BLC3001 A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations NCT02365597 - 42756493BLC2001 An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Proposal Review	
Question 1: The clinical trial data from the study/studies listed above were previously identified and approved as being available for a data sharing request. Is there any reason why the study/studies listed should no longer be shared?	No
Comments if 'Yes':	
Question 2: On review of the proposal, is there any data that has been requested that may be missing from the clinical database?	No
Comments if 'Yes':	
Question 3: Is a similar analysis underway, or completed and pending disclosure by J&J?	No
Comments if 'Yes':	